Managing dyslipidemia in HIV/AIDS patients: challenges and solutions

References

• BittarRGiralPAslangulEDeterminants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patientsAntivir Ther201217585586022318219
   PubMed Web of Science ®Google Scholar
• GrinspoonSCarrACardiovascular risk and body-fat abnormalities in HIV-infected adultsN Engl J Med20053521486215635112
   PubMed Web of Science ®Google Scholar
• LoJGrinspoonSCardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk?Curr Opin HIV AIDS20083320721319372968
   PubMed Web of Science ®Google Scholar
• DubéMPParkerRATebasPGlucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosidesAIDS200519161807181816227788
   PubMed Web of Science ®Google Scholar
• MotheBPerezIDomingoPHIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, SpainCurr HIV Res20097659760019929794
   PubMed Web of Science ®Google Scholar
• HejaziNRajikanRChoongCLSaharSMetabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional surveyBMC Public Health20131375823947428
   PubMed Web of Science ®Google Scholar
• ZouWBerglundLHIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular riskPrev Cardiol20071029610317392622
   PubMedGoogle Scholar
• MallewaJEHigginsSPGarbettSSaxenaNVilarFJCardiovascular disease risk management in HIV patients, experiences from Greater ManchesterInt J STD AIDS200920642542619451331
   PubMed Web of Science ®Google Scholar
• CalzaLManfrediRChiodoFDyslipidaemia associated with anti-retroviral therapy in HIV-infected patientsJ Antimicrob Chemother2004531101414645323
   PubMed Web of Science ®Google Scholar
• HruzPWMurataHMuecklerMAdverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanismAm J Physiol Endocrinol Metab20012804E549E55311254460
   PubMed Web of Science ®Google Scholar
• FauvelJBonnetERuidavetsJBAn interaction between Apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patientsAIDS200115182397240611740190
   PubMed Web of Science ®Google Scholar
• ViganòAAldrovandiGMGiacometVImprovement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected childrenAntivir Ther200510891792416430197
   PubMed Web of Science ®Google Scholar
• D:A:D Study GroupSabinCAWormSWUse of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationLancet200837196221417142618387667
   PubMed Web of Science ®Google Scholar
• BernalEMasiáMPadillaSGutiérrezFHigh-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen compositionAIDS Patient Care STDS200822756957518479224
   PubMed Web of Science ®Google Scholar
• PenzakSRChuckSKStajichGVSafety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infectionPharmacotherapy20002091066107110999499
   PubMed Web of Science ®Google Scholar
• GrinspoonSKGrunfeldCKotlerDPState of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summaryCirculation2008118219821018566320
   PubMed Web of Science ®Google Scholar
• ChuCUmanskiGBlankAMeissnerPGrossbergRSelwynPAComorbidity-related treatment outcomes among HIV-infected adults in the Bronx, NYJ Urban Health201188350751621302140
   PubMed Web of Science ®Google Scholar
• KaminDHadiganCHyperlipidemia in children with HIV infection: an emerging problemExpert Rev Cardiovasc Ther20031114315015030304
   PubMedGoogle Scholar
• MillerTIBorkowskyWDiMeglioLAMetabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected childrenHIV Med201213526427522136114
   PubMed Web of Science ®Google Scholar
• PatelKWangJJacobsonDLAggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virusCirculation2014129111204121224366631
   PubMed Web of Science ®Google Scholar
• EcheverríaPDomingoPLlibreJMPrevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patientsBiomed Res Int2014201482305825170515
   PubMed Web of Science ®Google Scholar
• WormSWDe WitSWeberRDiabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)Circulation2009119680581119188509
   PubMed Web of Science ®Google Scholar
• WormSWFriis-MøllerNBruyandMHigh prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndromeAIDS201024342743519910787
   PubMed Web of Science ®Google Scholar
• TriantVALeeHHadiganCGrinspoonSKIncreased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus diseaseJ Clin Endocrinol Metab20079272506251217456578
   PubMed Web of Science ®Google Scholar
• DAD Study GroupFriis-MøllerNReissPClass of antiretroviral drugs and the risk of myocardial infarctionN Engl J Med2007356171723173517460226
   PubMed Web of Science ®Google Scholar
• Menezes de PáduaCAMouraCSAvailability of data on adverse reactions to antiretroviral drugs in medical charts according to the Naranjo algorithm: an example of a Brazilian historical cohortClin Drug Investig2014346395402
   Web of Science ®Google Scholar
• KagarukiGBMayigeMTNgadayaESMagnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regionsBMC Public Health20141490425183300
   PubMed Web of Science ®Google Scholar
• NgalaRAFiankoKDyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi MetropolisAfr Health Sci20131341107111624940339
   PubMedGoogle Scholar
• JantarapakdeJPhanuphakNChaturawitCPrevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adultsAIDS Patient Care STDS201428733134024914459
   PubMed Web of Science ®Google Scholar
• TesfayeDYKindeSMedhinGBurden of metabolic syndrome among HIV-infected patients in Southern EthiopiaDiabetes Metab Syndr20148210210724907175
   PubMedGoogle Scholar
• PaulaAASchechterMTuboiSHContinuous increase of cardiovascular diseases, diabetes, and non-HIV related cancers as causes of death in HIV-infected individuals in Brazil: an analysis of nationwide dataPLoS One201494e9463624728320
   PubMed Web of Science ®Google Scholar
• TripathiAJerrellJMLieseADAssociation of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994–2011Metab Syndr Relat Disord201311641742623909647
   PubMed Web of Science ®Google Scholar
• LedergerberBFurrerHRickenbachMFactors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort StudyClin Infect Dis200745111111917554711
   PubMed Web of Science ®Google Scholar
• de WaalRCohenKMaartensGSystematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reactionPLoS One201385e6362323723990
   PubMed Web of Science ®Google Scholar
• KotlerDPHIV lipodystrophy etiology and pathogenesis. Body composition and metabolic alterations: etiology and pathogenesisAIDS Read200313Suppl 4S5S912762287
   PubMedGoogle Scholar
• LemoineMSerfatyLCapeauJFrom nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and managementCurr Opin Infect Dis2012251101622183113
   PubMed Web of Science ®Google Scholar
• ArendtBMMohammedSSMaDWNon-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid compositionCurr HIV Res20119212813521434863
   PubMed Web of Science ®Google Scholar
• Crum-CianfloneNKrauseDWessmanDFatty liver disease is associated with underlying cardiovascular disease in HIV-infected personsHIV Med201112846347121251186
   PubMed Web of Science ®Google Scholar
• AhmedMHByrneCDModulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)Drug Discov Today20071217–1874074717826687
   PubMed Web of Science ®Google Scholar
• AhmedMHByrneCDCurrent treatment of non-alcoholic fatty liver diseaseDiabetes Obes Metab200911318819518564173
   PubMed Web of Science ®Google Scholar
• PriceJCSeabergECLatanichRRisk factors for fatty liver in the Multicenter AIDS Cohort StudyAm J Gastroenterol2014109569570424642579
   PubMed Web of Science ®Google Scholar
• NishijimaTGatanagaHShimboTTraditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infectionPLoS One201491e8759624498148
   PubMed Web of Science ®Google Scholar
• SterlingRKSmithPGBruntEMHepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuseJ Clin Gastroenterol201347218218723059409
   PubMed Web of Science ®Google Scholar
• MachadoMVOliveiraAGCortez-PintoHHepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factorsHepatology2010521717820578130
   PubMed Web of Science ®Google Scholar
• Bani-SadrFBarangeKDaoudFPersistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosisHIV Med200910741742119490173
   PubMed Web of Science ®Google Scholar
• SattarNPreissDMurrayHMStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsLancet2010375971673574220167359
   PubMed Web of Science ®Google Scholar
• PreissDSeshasaiSRWelshPRisk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisJAMA2011305242556256421693744
   PubMed Web of Science ®Google Scholar
• CulverALOckeneISBalasubramanianRStatin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health InitiativeArch Intern Med2012172214415222231607
   PubMed Web of Science ®Google Scholar
• AthyrosVGMikhailidisDPPharmacotherapy: statins and new-onset diabetes mellitus – a matter for debateNat Rev Endocrinol20128313313422310848
   PubMed Web of Science ®Google Scholar
• AthyrosVGTziomalosKKaragiannisAMikhailidisDPLipid-lowering agents and new onset diabetes mellitusExpert Opin Pharmacother201011121965197020486831
   PubMed Web of Science ®Google Scholar
• HsiehMHLuPLKuoMCPrevalence of and associated factors with chronic kidney disease in human immunodeficiency virus-infected patients in TaiwanJ Microbiol Immunol Infect Epub1072013
   Google Scholar
• RaschMGEngsigFNFeldt-RasmussenBRenal function and incidence of chronic kidney disease in HIV patients: a Danish cohort studyScand J Infect Dis201244968969622680981
   PubMed Web of Science ®Google Scholar
• WyattCMThe kidney in HIV infection: beyond HIV-associated nephropathyTop Antivir Med201220310611022954611
   PubMedGoogle Scholar
• MadalaNDThusiGPAssoungaAGNaickerSCharacteristics of South African patients presenting with kidney disease in rural KwaZulu-Natal: a cross sectional studyBMC Nephrol2014156124731300
   PubMed Web of Science ®Google Scholar
• AhmedMHKhalilAAEzetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplantSaudi J Kidney Dis Transpl20102161021102921060168
   PubMedGoogle Scholar
• ParsaAABhangooAHIV and thyroid dysfunctionRev Endocr Metab Disord201314212713123743889
   PubMed Web of Science ®Google Scholar
• BeltranSLescureFXDesailloudRIncreased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screeningClin Infect Dis200337457958312905143
   PubMed Web of Science ®Google Scholar
• GómezQCVesgaGJLowenstein DeMEMass screening for hypothyroidism in a cohort of HIV infected patients in a Bogotá hospital, ColombiaRev Chilena Infectol20112815963 Spanish21526288
   PubMed Web of Science ®Google Scholar
• KetsamathiCJongjaroenprasertWChailurkitLOUdomsubpayakulUKiertiburanakulSPrevalence of thyroid dysfunction in Thai HIV-infected patientsCurr HIV Res20064446346717073621
   PubMed Web of Science ®Google Scholar
• WienerMLoYKleinRSAbnormal thyroid function in older men with or at risk for HIV infectionHIV Med20089754454918554308
   PubMed Web of Science ®Google Scholar
• NoureldeenAQustiSYKhojaGMThyroid function in newly diagnosed HIV-infected patientsToxicol Ind Health2014301091992523188649
   PubMed Web of Science ®Google Scholar
• de PommerolMHessamfarMLawson-AyayiSMenopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohortInt J STD AIDS2011222677221427426
   PubMed Web of Science ®Google Scholar
• KojicEMWangCCCu-UvinSHIV and menopause: a reviewJ Womens Health (Larchmt)200716101402141118062755
   PubMed Web of Science ®Google Scholar
• YinMTShuAZhangCATrabecular and cortical microarchitecture in postmenopausal HIV-infected womenCalcif Tissue Int201392655756523460340
   PubMed Web of Science ®Google Scholar
• FerreiraCEPinto-NetoAMCondeDMCosta-PaivaLMoraisSSMagalhãesJMenopause symptoms in women infected with HIV: prevalence and associated factorsGynecol Endocrinol200723419820517505939
   PubMed Web of Science ®Google Scholar
• LoutfyMRSonnenberg-SchwanUMargoleseSSherrLA review of reproductive health research, guidelines and related gaps for women living with HIVAIDS Care201325665766623088551
   PubMed Web of Science ®Google Scholar
• IbrahimN’MohamedNShuidANUpdate on statins: hope for osteoporotic fracture healing treatmentCurr Drug Targets201314131524153223876090
   PubMed Web of Science ®Google Scholar
• FournierJPDuijnhovenRGRenouxCDell’AnielloSKlungelOHSuissaSConcurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women: a population-based case-control studyMenopause20142191023102624937027
   PubMed Web of Science ®Google Scholar
• CardosoSWTorresTSSantini-OliveiraMMarinsLMVelosoVGGrinsztejnBAging with HIV: a practical reviewBraz J Infect Dis201317446447923711587
   PubMed Web of Science ®Google Scholar
• AhmedMHHamadMARouthCConnollyVStatins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actionsExpert Opin Pharmacother201112172673268122043827
   PubMed Web of Science ®Google Scholar
• AthyrosVGTziomalosKGossiosTDSafety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysisLancet201037697561916192221109302
   PubMed Web of Science ®Google Scholar
• AthyrosVGTziomalosKDaskalopoulosGNKaragiannisAMikhailidisDPStatin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?Ann Med201143316717121476786
   PubMed Web of Science ®Google Scholar
• AthyrosVGMikhailidisDPDidangelosTPEffect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised studyCurr Med Res Opin200622587388316709309
   PubMed Web of Science ®Google Scholar
• WilliamsDFeelyJPharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitorsClin Pharmacokinet200241534337012036392
   PubMed Web of Science ®Google Scholar
• PenzakSRChuckSKManagement of protease inhibitor-associated hyperlipidemiaAm J Cardiovasc Drugs2002229110614727985
   PubMedGoogle Scholar
• GerberJGRosenkranzSLFichtenbaumCJEffect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJ Acquir Immune Defic Syndr200539330731215980690
   PubMed Web of Science ®Google Scholar
• MelroeNHKopaczewskiJHenryKHuebschJIntervention for hyperlipidemia associated with protease inhibitorsJ Assoc Nurses AIDS Care1999104556910394560
   PubMedGoogle Scholar
• DubeMPSteinJHAbergJAGuidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials GroupClin Infect Dis200337561362712942391
   PubMed Web of Science ®Google Scholar
• SchambelanMBensonCACarrAManagement of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelJ Acquir Immune Defic Syndr200231325727512439201
   PubMed Web of Science ®Google Scholar
• LoJDyslipidemia and lipid management in HIV-infected patientsCurr Opin Endocrinol Diabetes Obes201118214414721297466
   PubMedGoogle Scholar
• SolerADeigEGuilJRodríguez-MartinMGuelarAPedrolEEffectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemiaMed Clin (Barc)20061277250252 Spanish16942727
   PubMed Web of Science ®Google Scholar
• JacobsonTAComparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsAm J Cardiol20049491140114615518608
   PubMed Web of Science ®Google Scholar
• BonnetFAurillac-LavignolleVBreilhDPravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized studyHIV Clin Trials200781536017434849
   PubMed Web of Science ®Google Scholar
• SteinJHMerwoodMABellehumeurJLEffects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitorsAm Heart J20041474E1815077088
   PubMed Web of Science ®Google Scholar
• AbergJAZackinRABrobstSWA randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087AIDS Res Hum Retroviruses200521975776716218799
   PubMed Web of Science ®Google Scholar
• CalzaLColangeliVManfrediRRosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot studyAIDS200519101103110515958843
   PubMed Web of Science ®Google Scholar
• AhmedMHRosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangersMed Hypotheses200666244044116223568
   PubMed Web of Science ®Google Scholar
• CalzaLManfrediRColangeliVPocaterraDPavoniMChiodoFRosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitorsCurr HIV Res20086657257818991624
   PubMed Web of Science ®Google Scholar
• AslangulEAssoumouLBittarRRosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trialAIDS2010241778319838098
   PubMed Web of Science ®Google Scholar
• BottaroEGCaravelloOScapellatoPGRosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experienceEnferm Infecc Microbiol Clin2008266325329 Spanish18588813
   PubMed Web of Science ®Google Scholar
• SinghSWilligJHMugaveroMJComparative effectiveness and toxicity of statins among HIV-infected patientsClin Infect Dis201152338739521189273
   PubMed Web of Science ®Google Scholar
• BenesicAZillyMKlugeFLipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavirInfection200432422923315293079
   PubMed Web of Science ®Google Scholar
• CalzaLManfrediRChiodoFStatins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAARTAIDS200317685185912660532
   PubMed Web of Science ®Google Scholar
• WohlDAWatersDSimpsonRJJrEzetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapyClin Infect Dis20084781105110818781882
   PubMed Web of Science ®Google Scholar
• NegredoEMoltoJPuigJEzetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statinsAIDS200620172159216417086055
   PubMed Web of Science ®Google Scholar
• ChowDChenHGlesbyMJShort-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patientsAIDS200923162133214119770624
   PubMed Web of Science ®Google Scholar
• Berg-WolfMVKlibanovOMGaughanJPTedaldiEMEzetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patientsAIDS Patient Care STDS Epub572008
   Web of Science ®Google Scholar
• ChastainLMBainAMEdwardsKLBedimoRBustiAJA retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemiaJ Clin Lipidol20071663463921291706
   PubMed Web of Science ®Google Scholar
• BennettMTJohnsKWBondyGPEzetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIVLipids Health Dis200761517565701
   PubMed Web of Science ®Google Scholar
• SamineniDFichtenbaumCJFenofibrate in the treatment of dyslipidemia associated with HIV infectionExpert Opin Drug Metab Toxicol201068995100420604734
   PubMed Web of Science ®Google Scholar
• BadiouSMerle De BoeverCDupuyAMBaillatVCristolJPReynesJFenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adultsAtherosclerosis2004172227327915019537
   PubMed Web of Science ®Google Scholar
• ThomasJCLopes-VirellaMFDel BeneVEUse of fenofibrate in the management of protease inhibitor-associated lipid abnormalitiesPharmacotherapy200020672773410853629
   PubMed Web of Science ®Google Scholar
• RaoAD’AmicoSBalasubramanyamAMaldonadoMFenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophyAm J Med Sci2004327631531815201643
   PubMed Web of Science ®Google Scholar
• FichtenbaumCJYehTMEvansSRAbergJATreatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087J Clin Lipidol20104427928720824151
   PubMed Web of Science ®Google Scholar
• BalasubramanyamACorazaISmithEOCombination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of “Heart Positive,” a randomized, controlled trialJ Clin Endocrinol Metab20119672236224721565796
   PubMed Web of Science ®Google Scholar
• GerberJGKitchDWFichtenbaumCJFish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186J Acquir Immune Defic Syndr200847445946617971707
   PubMed Web of Science ®Google Scholar
• SamsonSLPownallHJScottLWHeart Positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemiaContemp Clin Trials200627651853016914390
   PubMed Web of Science ®Google Scholar
• SouzaSAChowDCWalshEJFordS3rdShikumaCPilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemiaHawaii Med J201069512212520533755
   PubMedGoogle Scholar
• GerberMTMondyKEYarasheskiKENiacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapyClin Infect Dis200439341942515307011
   PubMed Web of Science ®Google Scholar
• DubéMPWuJWAbergJASafety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148Antivir Ther20061181081108917302378
   PubMed Web of Science ®Google Scholar